Sulfatinib,
1308672-74-3,
surufatinib,
KDR-IN-1,
HMPL012,
N-(2-(dimethylamino)ethyl)-1-(3-((4-((2-methyl-1H-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide,
UNII-B2K5L1L8S9,
B2K5L1L8S9,
1816307-67-1,
Benzenemethanesulfonamide, N-(2-(dimethylamino)ethyl)-3-((4-((2-methyl-1H-indol-5-yl)oxy)-2-pyrimidinyl)amino)-,
Benzenemethanesulfonamide, N-[2-(dimethylamino)ethyl]-3-[[4-[(2-methyl-1H-indol-5-yl)oxy]-2-pyrimidinyl]amino]-,
N-[2-(dimethylamino)ethyl]-1-[3-[[4-[(2-methyl-1H-indol-5-yl)oxy]pyrimidin-2-yl]amino]phenyl]methanesulfonamide,
Surufatinib [INN],
Sulfatinib [WHO-DD],
Sulfatinib; HMPL-012,
GTPL9769,
HMPL-012,
SCHEMBL1822601,
TTZSNFLLYPYKIL-UHFFFAOYSA-N,
BCP14757,
EX-A2524,
KS-00000TW5,
AKOS030632837,
ZINC117218067,
CS-5949,
AK549548,
HMPL-012;HMPL 012;HMPL012,
HY-12297,
VEGFR2 inhibitor [WO2011060746],
N-(2-(dimethylamino) ethyl)-1-(3-((4-((2-methyl-1H-indol-5-yl)oxy)pyrimidin-2-yl)amino)phenyl)methanesulfonamide,